Floatz logo

21 assets in Prolymphocytic Leukemia

Therapeutic assets addressing Prolymphocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2BBB (72)
Fludarabine
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP3BB (69)
Cyclosporin A
Prolymphocytic Leukemia
Fred Hutchinson Cancer CenterP3BB (67)
Nivestim
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2BB (67)
Tacrolimus
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2BB (66)
Busulfanum
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2BB (65)
Melphalan
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2BB (65)
Ibrutinib
Prolymphocytic Leukemia
Fred Hutchinson Cancer CenterP2B (63)
Rituximab
Prolymphocytic Leukemia
Acerta Pharma BVP2B (63)
Sirolimus
Prolymphocytic Leukemia
Masonic Cancer Center, University of MinnesotaP3B (61)
Allopurinol
Prolymphocytic Leukemia
Masonic Cancer Center, University of MinnesotaP2B (57)
Thiotepa
Prolymphocytic Leukemia
Fred Hutchinson Cancer CenterP2B (57)
Abatacept Recombinant
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2CCC (53)
Acalabrutinib
Prolymphocytic Leukemia
Acerta Pharma BVP1/2CCC (53)
Mesna
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2CCC (53)
Ptcy
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2CCC (53)
Ruxolitinib
Prolymphocytic Leukemia
Center for International Blood and Marrow Transplant ResearchP2CCC (53)
Treosulfan
Prolymphocytic Leukemia
Fred Hutchinson Cancer CenterP2CCC (53)